This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk13: Good day and thank you for standing by. Welcome to the Redland Pharmaceuticals third quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, it will be a question and answer session. To ask a question during the session, you will need to press star 101 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 101 again. Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Connolly, Investor Relations and Corporate Communications. Please go ahead.
spk14: Thank you, Victor. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section on the Investors page of our website at ir.rhythmtx.com. This morning, we issued our press release that provides our third quarter 2023 financial results and a business update, which is available on our website. As listed on slide two, here with me today in Boston are David Meeker, Chair, Chief Executive Officer and President of Earthen Pharmaceuticals, Jennifer Chen, Executive Vice President, Head of North America, Hunter Smith, our Chief Financial Officer, and Jan Mazerow, Executive Vice President, Head of International, is joining us on the line from Europe. On slide three, I'll remind you that this call contains remarks concerning future expectations, plans, and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC. In addition, any forward-looking statements represents our views only as of today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements. With that, I'll turn the call over to David Meeker, who will begin on slide five.
spk11: Thank you, Dave, and good morning, everyone. Thank you for joining the call. So we're pleased to report out another very strong quarter with continued execution across all parts of our business. The two near-term drivers of Rhythm Value building the BBS commercial opportunity globally and enrollment into our Phase 3 HO trial remain on track. I'm incredibly impressed by the performance of our North American and international organizations. BBS and the monogenic forms of MC4R pathway diseases we are approved to treat are, as we have discussed multiple times, highly meaningful rare disease opportunities. But they do fall in the ultra-rare category, with all of the challenges these patients face getting to a diagnosis and then accessing the appropriate therapies. The sheer volume of noise around the management of obesity as a disease and the use of GLP-1 specifically has both aided the cause, healthcare providers are looking more closely at patients who present with obesity and doing the appropriate workups, and hindered the cause, where the availability of powerful therapies such as GLP-1 medications has led many to believe that all obesity is the same and GLP-1 represents a universal solution. As we know, that is not correct. Obesity is not one disease, but many diseases, and as with most forms of medical therapy, the more targeted and specific the solution, the better. The medical community continues to learn more about the factors which control hunger, the role of the different pathways, and the effect of different drugs play in modulating those pathways. Our story remains relatively simple. We're replacing or supplementing a hormonal signal, which is deficient. So if you're managing a patient, why wouldn't you start there? Revenues in the quarter came in at $22.5 million, showing exactly the steady growth we had hoped to see. We're pleased with the script volume in the U.S., where the team is doing a great job educating on the MC4 pathway and the value of precision therapy. And we're incredibly excited to cross the 100-patient threshold in Europe, where in addition to the usual challenges facing rare disease communities, market access across the different healthcare systems can be particularly challenging. We have experienced teams in all geographies who are remarkably skilled at navigating these challenges. So although it will never be easy, patient by patient, we find solutions. As you know, we do not provide financial guidance, but for those of you building models, my experience working in rare diseases with many similarities to our current world has taught me it never gets easier. The revenue trajectory does not inflect, but these opportunities continue to grow over time. HO Phase III enrollment continues on track with two-thirds of the patients screened. That's our proxy for enrollment as almost none of these patients screened fail. The majority of patients needed to complete enrollment have their screening visits already scheduled, and we still have sites who are just opening or scheduled to open and who are eager to get their patients enrolled. We did get early access approval for HO in the third quarter in France based on the 18 patient Phase II data alone. This is an incredible recognition of both the unmet medical need in this population and the potential significant impact treatment may have. The first patient, as Jan will outline, should be treated before year end. Finally, we look forward to providing additional updates at our R&D day, particularly with regard to our next generation weekly formulation, the Daybreak Trial, and our pediatric results. So moving to slide six, we recently had a separate analyst call following a very successful TOSS meeting in Dallas with multiple presentations, which are outlined here. What's particularly gratifying about these meetings, it's the opportunity to meet with the community in person and feel, literally, the growing interest and learning more about the different forms of obesity, including MC4R pathway diseases. On slide seven, I want to take you through all of the 12-month HO data that we reviewed on the last call. Fourteen patients entered the long-term extension, and the results for all 14 are shown in this slide. We saw a robust mean 25% BMI decrease across the 12 patients who had 12 months of data. And I remind you that this is a blend, this trial is a blend of ages with 11 of 12 of the patients, pediatric patients. And the pediatric patients are growing where you would expect the BMI to actually increase with that growth. The two panels on the right are the two patients who are off treatment for some period of time. The short message here is if you take the therapy, most patients respond. And when you stop treatment, i.e., you stop this hormonal replacement therapy, your BMI weight increases. Finally, there's growing interest in the quality of the weight loss, meaning losing fat mass is good, but losing large amounts of lean mass is not good. Our early results suggest we do pretty well in that category, as shown on the DEXA scan results, which we presented on the poster. And one other graphic on the poster shows the shift in obesity class experience by the patients, with three of the pediatric patients actually getting back into the normal BMI range for their age. Slide 8, this is just to remind you of the trial design where we are targeting 120 patients, and as noted, two-thirds of the patients have been screened, and the majority of the balance of patients needed to complete the trial have already scheduled their screening visits. And importantly, and I think this is, you know, it's kind of still early here, but quite noteworthy, of the patients treated, we've had almost no trial discontinuations. So finally on slide nine, this slide is to remind you that we are working on meaningful opportunities. You could build a very profitable company around BBS and the POMC and LEPR monogenic opportunities we are approved for today. However, we are investing significantly in R&D because those opportunities that we are pursuing are even greater. And as you know, for example, the HO opportunity itself represents a large, well-identified patient population with no approved therapy. And with that, I'll turn the call over to Jennifer.
spk07: Thank you, David. We are pleased with the continued progress we are seeing with our BBS commercial launch. Hundreds of patients with BBS in the U.S. are now realizing the benefits of emcevery therapy. We continue to hear the positive, life-changing impact we are making to the lives of patients and families. Recently, we heard from one mother whose son is on emcevery therapy, and emcevery has had a profound effect on his weight and his hyperphagia. He is full for the first time, leaves the dinner table before everyone else in the family, And for the very first time, he told his mother he does not like certain foods like lima beans, tomatoes, and pickles. In the mother's words, we are experiencing him as a kid, not a hungry kid. And Sivri is the only therapy approved specifically to treat obesity due to BBS. And we are thrilled to hear these stories from patients and families who now have access to therapy. Beginning on slide 11, We are pleased with the growth and consistent strong demand for MCIVRI over the first five quarters. Throughout the launch from June 16, 2022 through the end of the third quarter of 2023, we now have received more than 545 new BBS prescriptions, coming from more than 300 prescribers. Of these prescriptions, we have greater than 330 approvals for reimbursement from payers. On the next slide, I will cover results within the third quarter. We received greater than 120 prescriptions with 80 approvals within the third quarter. Several of these approvals were from prescriptions received within the quarter, while others were written in prior quarters. We continue to identify more BBS patients and work to speed diagnosis. Our active engagement with physicians remains focused on disease awareness, diagnosis, and the benefits of MCFRI. And our Rhythm and Tune team continues to deliver support to provide both to patients and families and healthcare providers every step of the way. Next slide. Here is a snapshot of the patients with BBS behind these prescriptions. We continue to see an upward trend in terms of prescriptions received from adult patients. As we've touched on before, this trend diverges from the age distribution in the CRIBS registry, a global registry housing data on BBS patients, where approximately 80% of registry participants are 18 or younger. We believe this trend is representative of adult patients who simply aged out of participating in this annual survey or who were lost to follow-up. Once MCIVRI was approved, through our education efforts, many of these patients were re-engaged with their physicians. This is not uncommon in rare disease, where the first approved therapy for a disease causes not only increased awareness of the disease, but also allows for increased re-engagement of the broader diagnosed patient population. Next slide. Onto prescribers. Endocrinology, both adult and pediatric, remains consistent over the last few quarters as our top specialty, accounting for 45% of prescribers. We are seeing an increase in the portion of new to rhythm prescribers, or physicians our territory managers had not previously called on directly prior to prescription, which now accounts for 28% of our prescriber base. This reinforces the conviction we have in our non-personal promotion efforts. Lastly, we are seeing an increase in the depth of prescribers as 28% of them have written more than one prescription launched to date, which is up from 25% as reported on the last quarterly call. We remain focused on a greater breadth of prescribers over time, as well as more and more physicians who identify additional patients and prescribe in SIFRI for the second or more patients based off their own positive experience. Next slide. Access and reimbursement remain consistent with regard to overall coverage by state Medicaid and the overall payer mix. If we look at Medicaid coverage through Covered Lives, launched to date, approximately 80% of Medicaid Covered Lives are in states with either a positive and slippery policy in place or in a state where we have been able to gain positive coverage in at least one instance in the absence of an MCFRI policy. The remaining 20% of Medicaid lives represent states where we either have not yet had a prescription for MCFRI that would trigger a coverage decision, or we are still working to secure access for a prescription, or finally, where we have not been successful in gaining access through the appeals process. The payer mix for BVS remains consistent as almost 90% of prescriptions since launch fall under commercial or Medicaid plans. The average timeframe for approval is approximately one to three months, with some TILs extending out several months, consistent with our previous report. Overall, we are pleased with achievements to date in securing approvals. Next slide. Now, more than one year into launch, we are seeing a very strong rate of reauthorizations for continued and civil coverage, with approximately 75 positive reauthorization decisions. The vast majority of these reauthorizations are approved initially, and we have seen roughly a half dozen positive reauthorization decisions come upon appeal. Most of these positive appeals had required additional clinical documentation to allow for a reauthorization approval. We have had a few denials to date, and we are in the process of appealing. To provide some color on these, we have patients who have experienced overall clinical benefit but have not achieved 5% body weight loss. For example, one had a reauthorization within four months of its re-initiation. while our label outlines a 12-month efficacy touchpoint. Another patient saw other clinical benefits and was just shy of the 5% waste loss requirement. In both cases, we are working with the advocating physician and patient through the appeals process. Next slide and final slide for me. We were very pleased to announce that a new ICD-10 diagnosis code was established for BVS. This is a long-term positive for the BBS community and for Rhythm, as this improves understanding of the diagnostic and treatment journeys of patients and may enhance access to physicians with BBS patients. We remain focused on engaging with the community to find already diagnosed patients while expediting the identification of individuals with BBS who do not yet have a diagnosis. We are excited about our progress and the opportunities in front of us. With that, I'll hand it over to Yoann.
spk09: Thank you, Jennifer, and good morning. Slide 19. Today, we are very pleased to announce that we have achieved a significant international milestone with more than 100 patients from 11 countries outside of North America on the reimbursed therapy as of the end of October. Our first patients on reimbursed drugs started with the AP2 program in France for POMC and LIPAR deficiencies in March of 2022, and it has been gradual and steady built since then, as new countries came online for POMC and LIPAR, and that continues as new countries come online for BBS, beginning with reimbursed early access in France and now fully launched in Germany. Regarding the French AP1, pre-EME approval reimbursed early access program for hypothalamic obesity. We are now working through the process to get it started. This program often starts slow because of the administrative requirements. We have not treated any patients yet under this program, but we may be in position to treat a few patients during the fourth quarter. Overall, Europe is a key market for rare diseases for rhythm. European countries typically are better organized and more centralized in their approach to rare diseases compared to the United States. Even though these diseases are quite rare, the opportunity is meaningful. As a reminder, in the EU-focused UK, we estimate the prevalence for barley beetle syndromes to be 4,000 to 5,000 patients, which is a prevalence similar to the US. And we have already more than 1,500 patients identified in these countries. We are pleased with progress to date in achieving market access for incivary in a large number of international markets. Next slide. Our launch in Germany is off to a solid start following the unanimous decision of the German Federal Joint Committee or GBA to exclude MCRE from Germany's lifestyle exemption list and thereby make it eligible for full reimbursement for BBS. Our team is focused on engaging with physicians caring for patients with BBS and with many centers where they are treated. Building off our initial launch in Pomsi and Lipa, we had a very well-established relationship in place, as a handful of key experts already had positive experience within CERI. In addition, we benefited from a full commitment from key treatment centers, and in parallel, our German team continued engaging with additional large academic centers in Germany's decentralized healthcare system. We are seeing strong adherence to therapy, thanks to our Rhythm at Home patient support program. Similar to the U.S. Rhythm Intune Program, we provide support tailored specifically for each patient and their caregivers. For some, our support may come via phone calls. Others may receive at-home visits and injection support. Based on what we know about typical rare diseases drug launches in Germany, we expected a steady and methodical start. with a strong foundation in place based on the POMC-LIPA experience, continuously increasing numbers of EBS treatment centers and the positive impact of RISM at home, we are very well positioned to achieve continued success in Germany. Next slide. More broadly, we are making tremendous progress in engaging physicians throughout Europe. We had a very strong presence at the European Society for Pediatric Endocrinology in September with four oral presentations. Two presentations showcase data that demonstrates set malignant types potential to reduce risk of metabolic syndrome, cardiovascular disease, and type 2 diabetes in pediatric patients with POMC or lipar deficiency or Bard-Evidel syndrome. We also presented data from a raw genetic testing program through which we have collected more than 2,000 sequencing samples from individuals with severe obesity and hyperfuture. In addition, we hosted a symposium titled, Hyperphagia and Early-Anset Severe Obesity, the Role of Precision Medicine in the Treatment of FC4-R pathway disease. As you can see on this slide, it was very well attended. We had, in fact, 400 physicians in the room. We look forward to continuing this momentum at our second international meeting on pathway-related obesity, the IMPROVE conference in December in Paris. We are looking forward to a series of presentations, discussions, and engagement focusing on rare MC4 pathway diseases, monogenic ones, syndromic like BBS, and hypothalamic obesity, with more than 150 leading physicians and scientists coming from more than 10 countries. With that, I will turn the call over to Hunter in Boston.
spk08: Thank you, Yann. Rhythm remains tightly focused on global execution of commercial strategy across both our North America and international regions and continued development of the potential of Incivri and our pipeline, all while staying committed to financial discipline and delivering shareholder value. Let's start with a snapshot of the Q3 P&L on slide 23. We recorded $22.5 million in net product revenue in the third quarter versus $4.3 million during the same quarter last year, an increase of $18.2 million. Q3 last year was our first full quarter of BBS commercial sales in the United States, which followed FDA approval on June 16, 2022. Quarter over quarter, we saw an increase of $3.3 million, or 17%, in net product revenue, driven by continued growth in the number of patients on Omsibri therapy in both the U.S. and international regions. In last quarter's results, we highlighted that $1.6 million of our revenue resulted from shipments to our specialty pharmacy in excess of amounts that it dispensed to patients. resulting in an increase in inventory days on hand at quarter end. This quarter, shipments to the SP and dispenses to patients were very closely matched, resulting in a de minimis difference in value. Because of the larger number of patients on incivary therapy at the end of the third quarter, inventory days on hand at the SP decreased, but remained within a normal range. Gross to net for U.S. sales quarter over quarter decreased to 83% from 85% in the second quarter, primarily due to a Medicaid rebate adjustment in that quarter. Our practice is to accrue for Medicaid rebates based upon expected payer mix, and when actual Medicaid invoices are received, this may result in differences versus accrued amounts. Cost of sales during the third quarter was $2.4 million, or approximately 10.7% of net product revenue, representing a slight percentage decrease quarter over quarter. Cost of sales consisted primarily of product costs, our 5% royalty to Ipsen under our original licensing agreement for set melanotide, as well as amortization of previously capitalized sales-based milestone payments. R&D expenses were $33.6 million for the third quarter of 2023 compared to $21.1 million during Q3 2022, and essentially flat compared to Q2 2023 R&D expenses of $33.5 million. as G&A expenses were $30.5 million for the third quarter this year versus $21.9 million for the third quarter of 2022, and also essentially flat quarter over quarter versus $30 million in the second quarter of 2023. In the third quarter, weighted average common shares outstanding were $57.9 million, an increase of approximately 1 million shares over last quarter, resulting primarily from our equity issuance under the ATM program during the quarter. Quarterly net loss per share was $0.76. Now on slide 24, with the third and final investment tranche of $25 million from our capped royalty financing agreement with healthcare royalty partners and gross proceeds of approximately $50 million from our ATM program during the quarter, we are very well financed with $299.3 million in cash on hand. This cash on hand is sufficient to fund all planned activities into 2026. On the net revenue for this quarter of $22.5 million, 80% of these revenues were generated in the United States. The proportion of revenue generated by our international region increased from 14% to 20% quarter over quarter. Year-to-date net revenue was $53.2 million, and North America's sales account for 83% of that total. International sales growth continues with much of the quarter over quarter increase due to sales in Germany following the BBS launch, with this third quarter being the first full quarter of BBS sales in Germany. as well as an increase in patients with BBS in France receiving commercial drug as part of the French AP2 program for reimbursed early access. Third quarter operating expenses included total stock-based compensation of $8.5 million for the quarter, which represents $23.9 million in OPEX year-to-date. Lastly, we have narrowed the range of our non-GAAP operating expense guidance for 2023 to between $210 and $220 million. Please note that this amount excludes stock-based compensation. With that, I'll turn the call back over to David.
spk11: Thanks, Hunter. So I think hopefully you've heard we're really happy with how the commercial opportunity is beginning to develop here, obviously in the US. And now you've heard international is becoming an increasingly important part of this overall picture, as it will continue to do going forward. And on the HO side, just to highlight a moment of thanks here, I think thanks to our investigators and the patient community who have been incredibly engaged here and supportive of getting this trial going. Not an easy trial. It's a double-blind placebo-controlled to one, but, you know, you sign up, there's a chance you'll end up for a year on a placebo therapy. So, again, I've been really pleased with the reaction from the community and their engagement here and the A final note, thanks to the Rhythm team, and not an easy trial. It's a complicated trial with a lot of information. Important information will be one of the, perhaps our last chance to get this kind of robust information in a controlled trial setting. So they've done a great job, again, getting us to this position and putting us in place to be able to meet our end-of-the-year enrollment targets. So with that, we'll open it up to questions.
spk13: Thank you. And as a reminder, to ask a question, please press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. One moment for our first question. Our first question comes from the line of Corin Jenkins from Goldman Sachs. Your line is open.
spk01: Good morning. Thanks for taking our question. I asked a couple from us, maybe first, how should we think about the development for RM718 as compared to the way you developed in Sivri? Will it largely mirror, or are there some kind of faster paths that you can take on that asset? And then as a follow-up, kind of separate question, where are the bulk of these 100 international patients, both with respect to region as well as BBS versus the PPL indication, and how does that kind of compare to where you were at the end of September?
spk11: Thanks, Corinne. So I'll take the first one and then Jan, I'll turn it over to you. So on 718, there is a faster path. I mean, you remember the very first trials that were done were in Sivri, were done in POMC, leptin receptor biallelic patients. Again, we were learning about dosing. There was a lot of, just we had to learn about the mechanism. So we benefit from all of that prior learning. HO, we had no clue of at that point. And HO, as we have seen, looks like a very sensitive model here. So again, a a great place to start. So the strategy for 718 will be after we've done our normal volunteer SAD-MAD, the single ascending dose and multiple ascending dose portions of that volunteer study. We'll have a cohort of HO patients, which hopefully will give us the insight that we need for dosing to then go to the additional indications. So it should go faster. It will go faster. There's no question it will go faster. Jan, on the 100 patients?
spk09: Yes, so first of all, in terms of geographic repartition, two-thirds of the patients are in France and in Germany, and the rest spread across four or five countries, Turkey, Italy, Netherlands, UK. The split between POMC, Lipar, and DBS, right now it's about 50-50, which is the reason because we did launch POMC and Lipar first. But given the more important prevalence BBS, we will catch up quickly and BBS will outpace from CNV part soon.
spk01: Very good. That's helpful. Thank you.
spk06: Next question. One moment for our next question.
spk13: And our next question comes from Phil Nadeau from TD Callan. Your line is open.
spk10: Good morning, congrats on the progress and thanks for taking our questions. Three from us, two pipeline and one commercial. On the pipeline, in terms of the HO Pivotal Study, should we look at the 25.5% mean BMI reduction that was shown in the 12-month extension as a reasonable proxy for what could be seen on the primary endpoint in the HO Pivotal? That's the first question. Second, any update on the M&A enrollment? And then third, in terms of commercial, Curtis, to hear your most recent estimates of how penetrated the U.S. diagnosed BBS market is, any sense of the number of diagnosed patients that are out there today? Thanks.
spk11: Sure. So let me take the first two. So is the 25% a good proxy? I mean, obviously, that's an incredibly robust result. We're very happy. I've said many times it's It's a little bit less about the magnitude of the change because we have a heterogeneous group of patients. We have very young kids. We have older adults. We're mixing them all together. That confounds a little bit. That number is going to read through. But what is remarkable is the consistency of the response. I mean, literally every patient in that trial, if they took the medication, is having a response. So we're powered for a 10% difference. I think there's little risk, knock on wood. that, you know, we wouldn't do better than that. And the 25% speaks to, you know, that level of it. We're highly powered, 99% better powered to show the temperature. So it's a long way of saying, I don't think you can take the 25% necessarily as a read-through, but it's highly in this patient group. And then emanate. So we're making progress there. Again, I'm know we haven't highlighted it so much because we're still it's still a work in progress but i think we sorted out um the issues which uh you know put us well behind here on that trial and that trial is now in running uh enrolling strongly uh a couple of the cohorts are enrolling ahead of uh you know two of the other cohorts which is not unexpected um we didn't expect all four so i think what what we'll do is we'll we'll be reading out in 24 um sorry we'll announce in 24 that we fully enrolled it's a year study once we're fully enrolled um for uh when at least two of those cohorts have enrolled uh and then on the um the commercial side in terms of penetration jennifer i mean again we we make these epidemiologic estimates of four to five thousand and there's uncertainty in those numbers but how do you think penetrating against that um
spk07: So we have not updated the number of patients that have been diagnosed. I will just say that we've been focusing more in terms of those who have had a prescription. But with that said, the teams are doing an amazing job just in terms of the education efforts, and we continue to get more and more patients or find ACPs that have BBS patients or educating to have them also diagnose additional patients. I would say that in terms of, you know, opportunity that remains, there still remains a large opportunity in terms of not only the fines, but also the pull-through in terms of, you know, diagnosed patients to an emcee-free prescription. So lots of opportunities that still remain ahead.
spk10: That's very helpful. Thanks again for taking our questions.
spk13: Thank you. And one moment for our next question. Our next question comes from Derek Archila from Wells Fargo. Your line is open.
spk04: Hey, good morning. Thanks for taking the questions and congrats on the progress here. So just two from us. So I guess of the physicians that have written more than one script for BBS, I guess, how long between the first script do they write the second? And I guess, do you find the driver being them going out and finding more patients or just getting more experience with the drug and they already have patients that they're treating and then they start treating those. So that's question one. And then the second, I guess, what is left to be done to get HO patients on Incivry under the AP1 system in France? I guess, how do we think about the magnitude of the impact next year on new patients on therapy from that? Thanks. Yeah. Jennifer, first.
spk07: Yeah. So I would say that the timing is variable because the situation is also variable physician by physician. Some were physicians that had more than one patient even prior to our launch. And that could take time just in terms of that patient coming back in to have a dialogue with the physician just in terms of interest to get onto therapy. And then there's also others that, you know, through our education efforts, they diagnose the first patient and, you know, similar to rare disease, once you find that first patient, it's no longer this unicorn that's not in your practice, but something that you need to pay attention to just in terms of differential diagnosis of additional patients that have come to them in the past or will be coming to them in the future to remember that understanding the different symptoms to get to a clinical diagnosis is important to bear in mind. So it's a bit of a mix of both of them, and both of those also impact the timing in terms of the first to the next prescription. Great.
spk11: And Jan, maybe just a little bit more color on the process for the AP1-HO, and then how should we think about 2024?
spk09: Yes, sure. So first of all, of course, we are very pleased with this achievement. It's very rare to get such a pre-MEA approval in France based on phase 2 data. And to be more precise, there are just two rare disease therapies with such status in France. So as mentioned, we are now working through the process. And to answer to your questions, these programs of administrative requirements. So we get it granted, and now we have to go through a few steps. One is agreement in terms of data collections with the Centers of Reference and the French FDA. And the second is also the Centers of Reference are setting up multidisciplinary decision-making meetings to review the patient cases. So that's usual, and we have been through that with POMCILIPAR and also with DBS, so we know how it works, and it is the same for all the rare disease drugs. So those tests are currently, we are working on them. For your second question, in terms of number of patients, it's a bit difficult to say today what we know because it has been known and we have been reached out by a lot of experts, and we are working also with experts. There are a lot of patients who are in need, and we have a lot of physicians interested to treat these patients. So as soon as we will have these administrative requirements ready, We will have the first prescriptions, and the first patients will be treated. Still difficult to say how much in 2024.
spk11: More to come on that, Derek. We're learning here.
spk13: Thank you. Thank you. One moment on our next question. And our next question comes flying from . Your line is open.
spk03: Hey, good morning, guys. Thanks for taking the question and congrats on the progress. Two from us, one on the commercial and one on HO. So on the commercial front, I thought it was interesting you pointed out the divergence between your experience versus Cribs. Since you do have a significant proportion of prescribers being peed endos, I was wondering what kind of strategy are you thinking in terms of penetrating that segment to the market, I guess, a little bit more aggressively and have more representation in your prescriber base? And just to clarify on the nomenclature, is it your going guidance is going to be on prescriptions? Because you've previously talked about start forms. I just want to make sure that's what we should be looking at next. And then on HO, if you can maybe go into the screen failure commentary a little bit more, David. I guess what are the dynamics you're seeing with regards to enrollment and how are you balancing rapid enrollment to reach that 4Q completion date? and ensuring you avoid any compromises along the way. Thanks so much.
spk11: Oh, Jennifer?
spk07: So, sorry for clarification. The metric is the stop forms that we are focused on, and they're new stop forms, so not repeat scripts for the same patient. And regarding your question regarding the CRIPS piece, You know, for sure, the pediatric endocrinologist that is a treater and prescriber for MCIVRI remain a key specialty focus of our teams. And that's one that our territory managers are calling on. But we also supplement their efforts just with a lot of non-personal promotion efforts. upfront that when we took a look at that CRIB distribution of 80% less than 18 years of age, that these patients do not die at 18 years of age. And so we knew that there were a lot more patients either that were diagnosed and lost in the system And oftentimes, they may stop going to specific positions. So there was quite a breadth in terms of different specialties that we wanted to educate to get to those adults, which I think has been helpful in addition to the on-ground field team efforts in terms of getting to a distribution of patients that feels a bit more right just based off of the, you know, the age distribution of BBS patients in general.
spk11: Great, thanks. And Dagon, on the HO, the screen failure rate, so just to put that number a little more specifically, I think we've had four screen failures with over two-thirds of the patients screened or actively in screening. And even in that small number of screen failures, we've had least one patient who's been brought back in to rescreen. There was a minor issue, and so they may have ultimately turned out to be not a screen failure. And the reason it's so low is when we started this effort and we're looking and picking the sites, we probably had a total, the sites themselves had their list of patients, which were easily more than two times the number of patients we needed to enroll in this trial. So they were all starting with a list of patients. They weren't looking. And then they, as I said, they knew the entry criteria. They don't want to disappoint patients. So they're bringing in patients who they feel, based on their knowing the patient, that they meet entry criteria. and therefore the risk of screen failure is low. So in pushing to enroll this trial, I have no fear, if you will, that we're going to have a low-quality patient enrollment, meaning people are working on the edges. I think we're going to have patients who very much meet entry criteria because there's, like I said, a good selection of patients who are eager to get in.
spk03: Awesome. Thanks very much. Oh, yeah, that helps. Thank you so much.
spk13: Great. One moment for our next question. And our next question will come from the line of Jeff Hung from Morgan Stanley. Your line is open.
spk02: Thanks for taking my questions. You talked about a couple patients that didn't meet the 5% weight loss who are going through the appeals process. Do you have a sense for the proportion of BBS patients that discontinue based on the one-year recommendation? And then how does that compare to what you've seen for the other approved mutations? And then I have a follow-up. Yep, yep.
spk07: So the patients that I refer to just in terms of not meeting the REOS requirements for the 5% weight loss is really at this point just a handful of patients. There are not many that fall into that category, but even so, because of the belief from the physician as well as the desire for the patient to remain on therapy, we are helping them through the appeals process just in terms of trying to maintain them in terms of authorization there. You were asking a separate question, I believe, on the discontinuations on therapy overall. So we now do have a larger number of patients who have been on therapy for a longer period of time since our launch, and the discon rate to date has crept up a bit from the 10% that we had outlined to 13% of Rx's. The reasons why have not really changed just in terms of why they are disconning. I would characterize it as almost half of them for more personal reasons and about half of them for adverse event reasons. You know, it is still an opportunity, though, for our teams, just in terms of follow-up, because the hyperphagia, for those who are responding, does come back quickly, and they may, you know, consider coming back on therapy in the future.
spk02: Great, thanks. And you mentioned that about half or upwards of half of discontinuations are for personal reasons. Do you have any data indicating the proportion of those who discontinued were coming back to be treated again? And then my follow-up question was that for the prescribers who have not written more than one prescription. Are the main reasons because they're relatively new to prescribing Cetmelanotide or they don't have additional BBS patients or maybe something else? Thanks so much.
spk07: Yeah. So I'll answer the last question first. So the reasons are variable. They may only have one patient. You know, just in terms of a lot of our scripts also is, you know, patients who have been on therapy for a shorter period of time. That may be the case just in terms of the reasons for the one script. And it may also be the case just in terms of a physician having two patients where that patient either has not come in or is not ready to initiate therapy.
spk11: In terms of the other questions... The personal patients in the personal reason group and have any of those come back or...
spk07: I see. We don't have enough data right now in terms of that point just to outline, or I don't have it on me right now. I do know that there have been a couple of patients who discontinued and wanted to restart therapy because of the hyperphagia, but it's only a handful at this point in time.
spk11: The other thing, Jeff, just on the 5% in general in terms of how people experience benefit, this is a group, because of their underlying mechanism, their inability to respond to some of the other therapy, certainly diet and exercise and some of the other medications, isn't there. And so simply stopping the weight gain is a major advantage. And then, as Jennifer said, the overwhelming story we've heard as we've recounted on all these calls is just the quieting of their hyperphagia ability to leave the table, leave food on the table, is a pretty significant change for them. Great, thank you.
spk06: One moment for our next question.
spk13: And our next question, front line, Whitney Asian from Kennecore Genuity. Your line is open.
spk12: Hey, morning, guys. Going back to France and thinking particularly about BBS, can you remind us, I guess, where you are in the conversations for sort of regular way reimbursement. I know the logistics of the early access are slower than presumably it would be once you can flip over to regular reimbursement. So just curious where you are, the timing around that.
spk09: Sure. Yes, sure. So we have started the pricing negotiations with the pricing committee. It usually takes between nine months to two, three years. We think that we will have an end mid-next year, something like that. So we are in the third round technically, and so far it has been good from both an understanding of the unmet medical need and the benefit from MCV and also the relationship and the openness and the transparency in the discussion. So we are at the beginning for something that should end mid-next year.
spk12: Perfect. Thanks. And then on 718, I guess, can you remind us, I know you've talked about it being more potent in terms of its activity at the receptor. Is the idea behind the TPP there better weight loss kind of efficacy picture or lower dosing safety profile or just how you're thinking about that? Thanks.
spk11: Yeah, it's actually not that important. It's not more potent technically in terms of activity at the receptor, but it's more specific. So that's the major feature here, which is our current set melanotide. As you know, we hit both the MC4 and the MC1, which contributes to the hyperpigmentation. And so we've removed that It's very specific. So the probability we will have hyperpigmentation is low, and we have animal data to support that. So that's the major advantage here. And then, of course, it's weekly, so we have convenience, and, of course, we have an IP protection that goes out to 2041. And so those are the major elements that make this a really critical program for us.
spk12: Great. Thanks very much.
spk06: One moment for our next question.
spk13: And our next question comes from Joseph Stringer from Needham. Your line is open.
spk05: Hi, good morning. Thanks for taking our question. With regards to the upcoming Phase III readout and the two- to six-year-old BBS patients, just curious, through all the patient identification work that you've done for BBS to date in the U.S., how many do you estimate are in that two- to six-year-old range, and would you expect to see sort of a bolus, or how do you think that would impact the launch, if and when the label is expanded to include those patients.
spk11: Yeah, so maybe I'll lead, and Jennifer can add anything here. I think, A, it's not a large number of patients. What we see is a higher hit rate when a two- to six-year-old group is screened. That very early onset of obviously the history is very good there. They have true early onset obesity. And so the screening hit rate is a little bit higher in that group. And so that's an important part of this, number one. But it's not a large number of patients, so there won't be a big impact to the overall patient population. But I think what's really important about this, A, it's a genetic disease. You want to treat all patients. Getting in early is hugely important. So medically, I think this is very important. And it also builds, I think, an increasing recognition about what differentiates these diseases and the need to manage and think about them differently. So it will help us in different ways, but the absolute number will not be large.
spk05: Great. Thank you for taking our question.
spk13: Thank you. I'm not showing any further questions in the queue. I'd like to turn the conference back to David Meeker, Chairman, CEO, and President for closing remarks.
spk11: Thanks, Victoria. So thanks again, everybody, for tuning in and excited about the progress we're making, as you've heard. And we very much look forward to seeing everybody or hopefully people will be able to either show up in person or call into our R&D day on December 6th, where we have updates. We'll have a hypothalamic KOL from our hypothalamic obesity world. So that will be interesting in addition to the The data updates on our 718 program, the daybreak trial, and we will provide the data on the pediatric trial at that time. So with that, we'll sign off. Have a good day.
spk13: This concludes today's conference call. Thank you for participating. You may now disconnect. Everyone, have a great day.
Disclaimer